Bevacizumab: Mixed Results in Glioblastoma

Wolfgang Wick, MD


October 08, 2013

This feature requires the newest version of Flash. You can download it here.
In This Article

Glioblastoma: An Angiogenic Tumor

Hello. I am Professor Wolfgang Wick, Chairman of the Department of Neuro-Oncology, Heidelberg University Hospital in Heidelberg, Germany. Today I am going to summarize for you the findings on neuro-oncology, which is basically an update on glioblastoma from this year's European Cancer Congress (ECC) in Amsterdam.

Glioblastoma is a devastating disease with a median progression-free survival of just over half a year and median overall survival of 15-18 months. The standard of care consists of radiotherapy and chemotherapy, with temozolomide delivered during radiotherapy and for 6 more cycles after radiotherapy as a maintenance treatment. Improvement of this therapy is urgently needed, and a key target over the past years, both preclinically and clinically, has been angiogenesis. The glioblastoma is an extremely angiogenic tumor, and angiogenesis was tackled in the trials that I am going to discuss with the vascular endothelial growth factor (VEGF) inhibitor bevacizumab or with an anti-integrin, cilengitide, which is an RGD peptide that also targets the problem of neoangiogenesis -- pathological angiogenesis -- in this disease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: